Antiretroviral pharmacokinetics in the paediatric population: A review

Clinical Pharmacokinetics

Volumn 41, Issue 14, 2002, Pages 1115-1133

  King, Jennifer R ^a   Kimberlin, David W ^a   Aldrovandi, Grace M ^a   Acosta, Edward P ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CARBOVIR; CYTOCHROME P450; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LIVER ENZYME; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NUCLEOSIDE;

ABDOMINAL PAIN; AGE; AREA UNDER THE CURVE; CHILD DEVELOPMENT; CHILDHOOD DISEASE; CLINICAL TRIAL; CRYSTALLURIA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOXICITY; ENZYME ACTIVITY; FEVER; FLANK PAIN; GASTROINTESTINAL TRACT FUNCTION; GLUCURONIDATION; HEMATURIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION; LIFE EXPECTANCY; LIVER FUNCTION; NEPHROTOXICITY; PREMATURITY; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; CHILD; DOSE RESPONSE; DRUG ADMINISTRATION; METABOLISM; PEDIATRICS;

AGE FACTORS; ANTI-HIV AGENTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HUMANS; NUCLEOSIDES; PEDIATRICS; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0036437809     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241140-00001     Document Type: Review

References (68)

1. Elsberry VA. Principles of rational drug use in children. Clin Trends Pharm Prac 1995; 9 (5): 77-83
2. Yaffe SJ, Aranda JV, editors. Pediatric Pharmacology: Therapeutic Principles in Practice. 2nd Ed. Philadelphia (PA): WB Saunders Company, 1992: 16
3. Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook. 6th Ed. Hudson (OH): Lexi-Comp Inc, 1998
4. Kearns GL. Meeting the needs of the modernization act: Challenges in developing pediatric therapies. J Allergol Clin Immunol 2000; 106: S128-38
5. Jospe N, Forbes G. Fluids and electrolytes-clinical aspects. Pediatr Rev 1996; 17: 395-402
6. Evans WE, Schentag JJ, Jusko WJ, editors. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. 3rd Ed. Vancouver (WA): Applied Therapeutics, 1992
7. Shingadia D, Viani R, Rolando M, et al. Gastrostomy tube insertion for improvement of adherence to highly active antiretroviral therapy in pediatric patients with human immunodeficiency virus [abstract]. Pediatrics 2000; 105 (6): 1326
8. Gao WY, Shirasaka T, Johns DG, et al. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Biol Chem 1993; 91: 2326-33
9. Havlir DV, Tierney C, Friedland GH, et al. In vivo antagonism with zidovudine plus stavudine combination therapy. J Infect Dis 2000; 182: 321-5
10. Faletto MB, Miller WH, Garvey EP, et al. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob Agents Chemother 1997; 41: 1099-107
11. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection [Online]. Available from URL: http://www.hivatis.org/ [Accessed 2002 Sep 03]
12. Zidovudine (Retrovir) [Package Insert]. Research Triangle Park (NC): Glaxo Wellcome, 1998
13. Didanosine (Videx) [Package Insert]. Princeton (NJ): Bristol-Myers Squibb, 2000
14. Stavudine (Zerit) [Package Insert]. Princeton (NJ): Bristol-Myers Squibb, 2000
15. Lamivudine (Epivir) [Package Insert]. Research Triangle Park (NC): Glaxo Wellcome, 1999
16. Abacavir (Ziagen) [Package Insert] Research Triangle Park (NC): Glaxo Wellcome, 1998
17. Nevirapine (Viramune) [Package Insert] Columbus (OH): Roxane, 2000
18. Delavirdine (Rescriptor) [Package Insert] La Jolla (CA): Agouron, 2000
19. Efavirenz (Sustiva) [Package Insert]. Wilmington (DE): DuPont, 2000
20. Saquinavir (Fortovase) [Package Insert]. Nutley (NJ): Roche, 2000
21. Brundage RC, Kline MW, Lindsey JC, et al. Pharmacokinetics (PK) of saquinavir (SQV) and nelfinavir (NFV) in a twice-daily (BID) regimen in HIV-infected children [abstract 718]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco. Alexandria (VA): Foundation for Retorvirology and Human Health, 2000: 209
22. Ritonavir (Norvir) [Package Insert]. North Chicago (IL): Abbott, 2000
23. Indinavir (Crixivan) [Package Insert]. West Point (PA): Merck, 2000
24. Gatti G, Vigano A, Sala N, et al. Indinavir pharmacokinetics and pharmacodynamics in children with human immunodeficiency virus infection Antimicrob Agents Chemother 2000; 44: 752-5
25. Nelfinavir (Viracept) [Package Insert]. La Jolla (CA): Agouron, 2000
26. Acosta EP, Nachman S, Wiznia A, et al. Pharmacokinetic (PK) evaluation of nelfinavir (NFV) in combination with nevirapine (NVP) or ritonavir (RTV) in HIV-infected children-PACTG 403 [abstract 1642]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto. Washington, DC: Society for Microbiology, 2000: 334
27. Amprenavir (Agenerase) [Package Insert]. Research Triangle Park (NC): Glaxo Wellcome, 1999
28. Lopinavir/Ritonavir (Kaletra) [package insert]. North Chicago (IL): Abbott Laboratories, 2000
29. Gibb D, Barry M, Ormesher S. et al. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection. Br J Clin Pharmacol 1995; 39: 527-30
30. Kline MW, Dunkle LM, Church JA, et al. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics 1995; 96: 247-52
31. Veldkamp A, Van Heeswyk RPG, Scherpbier HJ, et al. The steady-state plasma pharmacokinetics of lamivudine and stavudine in HIV-1 infected children [abstract WePeB4124]. 13th International AIDS Conference; 2000; Durban, South Africa
32. Hughes W, McDowell JA, Shenep J, et al. Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children. Antimicrob Agents Chemother 1999; 43: 609-15
33. Luzuriaga K, Byrson Y, McSherry G, et al. Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis 1996; 174: 713-21
34. Willoughby R, Watson D, Welliver R, et al. Phase I evaluation of delavirdine in HIV-1-infected pediatric patients [abstract 1995]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco. Washington, DC: American Society for Microbiology, 1999: 522
35. Brundage RC, Fletcher CV, Fiske WD, et al. Pharmacokinetics of an efavirenz suspension in children [abstract 424]. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago. Alexandria (VA): Foundation for Retrovirology and Human Health, 1999: 147
36. Fletcher CV, Kline MW, Brundage RC, et al. Pharmacologic characteristics of saquinavir soft gelatin capsules (SQV-SGC) given with nucleoside antiretroviral agents (NRTIs) with and without nelfinavir (NLV) in HIV infected children [abstract 223]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago. Alexandria (VA): Foundation for Retrovirology and Human Health, 1998: 121
37. Mueller BU, Nelson RP, Sleasman J, et al. A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. Pediatrics 1998; 101: 335-43
38. Fletcher CV, Brundage RC, Remmel RP, et al. Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy. Antimicrob Agents Chemother 2000; 44: 1029-34
39. Krogstad P, Wiznia A, Luzuriaga K, et al. Treatment of human immunodeficiency virus-1 infected infants and children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis 1999; 28: 1109-18
40. Balis FM, Pizzo PA, Eddy J, et al. Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. J Pediatr 1989; 114: 880-4
41. Klecker RW, Collins JM, Yarchoan R, et al. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxy-thymidine: A novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases Clin Pharmacol Ther 1987; 41: 407-12
42. Boucher FD, Modlin JF, Weller S, et al. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr 1993; 122: 137-44
43. Mirochnick M, Capparelli E, Dankner W, et al. Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus. Antimicrob Agents Chemother 1998; 42: 808-12
44. Balis FM, Pizzo PA, Murphy RF, et al. The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Intern Med 1989; 110: 279-85
45. Stevens RC, Rodman JH, Yong FH, et al. Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. AIDS Res Hum Retroviruses 2000: 16: 415-21
46. King JR, Nachman S, Wiznia A, et al. Pharmacokinetics (PK) of enteric-coated didanosine (ddI EC) in HIV-infected pediatric patients [abstract 106]. Pharmacotherapy 2001; 21: 1272
47. Balis FM, Pizzo PA, Butler KM, et al. Clinical pharmacology of 2′,3′-dideoxyinosine in human immunodeficiency virus-infected children. J Infect Dis 1992; 165: 99-104
48. Mueller BU, Butler KM, Stocker VL, et al. Clinical and pharmacokinetic evaluation of long-term therapy with didanosine in children with HIV infection. Pediatrics 1994; 94: 724-31
49. Capparelli E. Pharmacokinetics of didanosine in HIV-infected infants [abstract A-63]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; Washington (DC): American Society of Microbiology, 1998: 20
50. Lewis LL, Venzon D, Church J, et al. Lamivudine in children with human immunodeficiency virus infection: A phase I/II study. J Infect Dis 1996; 174: 16-25
51. Mueller BU, Lewis LL, Yuen GJ, et al. Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother 1998; 42: 3187-92
52. Moodley J, Moodley D, Pillay K, et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998; 178: 1327-33
53. Kumar PN, Sweet DE, McDowell JA, et al. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency type 1-infected adults. Antimicrob Agents Chemother 1999; 43: 603-8
54. Johnson GM, Rodman JH, McDowell J, et al. Preliminary analysis of abacavir succinate (ABC) pharmacokinetics in neonates differs from adults and young children [abstract 720]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco. Alexandria (VA): Foundation for Retrovirology and Human Health, 2000: 209
55. Mirochnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. J Infect Dis 1998; 178: 368-74
56. Musoke P, Guay L, Bagenda D, et al. A phase I/II study of safety and pharmacokinetics of nevirapine in HIV-1 infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999; 13: 479-86
57. Starr SE, Fletcher CV, Spector SA, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. N Engl J Med 1999; 341: 1874-81
58. Debouck C. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res Hum Retroviruses 1992; 8: 153-64
59. Kohl NE, Emini EA, Schleif WA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A 1988; 85: 4686-90
60. Breilh D. Thuret I, Dumon C. et al. Population pharmacokinetic of ritonavir in 31 HIV-infected infants [abstract 1202]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sept 25-29; San Francisco. Washington, DC: American Society for Microbiology, 1999: 35
61. Burger DM, van Rossum AMC, Hugen PW, et al. Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children. Antimicrob Agents Chemother 2001; 45: 701-5
62. van Rossum AMC, de Groot R, Hartwig NG, et al. Pharmacokinetics of indinavir and low-dose ritonavir in children with HIV-1 infection. AIDS 2000; 14: 2209-19
63. Litalien C, Ciaquinto C, Faye A, et al. Nelfinavir doses should be increased in infants less than 3 months [abstract MoPeB2213]. 13th International AIDS Conference; 2000 Jul 9-14; Durban, South Africa. Fairfield (MN): Marathon Multimedia. 2000
64. Brundage RC, Fletcher CV, Fenton T, et al. Efavirenz (EFV) and nelfinavir (NFV) pharmacokinetics (PK) in HIV-infected children under 2 years of age [abstract 719]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco. Alexandria (VA): Foundation for Retrovirology and Human Health, 2000: 209
65. Capparelli E, Sullivan J, Mofenson L, et al. Pharmacokinetics (PK) of nelfinavir in HIV infected infants [abstract 1658]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto. Washington, DC: American Society for Microbiology, 2000: 338
66. Capparelli E, Burchett S, Kovacs A, et al. Nelfinavir (NFV) pharmacokinetics in combination with ritonavir (RTV) in infants and children with advanced HIV disease [abstract 661]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco. Alexandria (VA): Foundation for Retrovirology and Human Health, 2000: 199
67. Sadler BM, Gillotin C, Lou Y, et al. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob Agents Chemother 2001; 45: 30-7
68. Wintergerst U, Engelhorn C, Kurowski M, et al. Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected children. AIDS 2000; 14: 1866-7